Benefits of CELMoDs over IMiDs in multiple myeloma

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the differences between cereblon E3 ligase modulators (CELMoDs) including iberdomide and CC-92480 and immunomodulatory imide drugs (IMiDs) in the treatment of multiple myeloma. Whilst these compounds appear structurally similar to IMiDs, they are significantly more potent and allow overcoming resistance to lenalidomide and pomalidomide. Recent data has shown that CC-92480 is particularly effective in patients with extramedullary disease, especially in combination with other drugs like bortezomib. In addition, CELMoDs have a distinct toxicity profile, with the most common adverse event being myelosuppression. In the newly diagnosed and maintenance setting, these agents are also better tolerated than lenalidomide. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.